Radiation Therapy Using 3-Dimensional Treatment Planning in Patients With Non-small Cell Lung Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed non-small cell lung cancer
• •* Clinical stage T1-4, N0-2, M0
• •* Clinical stage T1-2, N0-1 must be medically inoperable
• •No distant metastases on history and physical exam, CBC, screening profile, CT or MRI of brain, CT of chest and abdomen (including adrenals and liver), and bone scan
• •No pleural effusions
• •Atelectasis not clearly distinguishable from tumor mass allowed provided all tumor and atelectasis together represent a volume that can be safely treated to the total dose delivered to gross disease
• •Diffuse pulmonary infiltrates thought to represent benign disease allowed only if representative lesion samples are proven by biopsy or cytology not to contain cancer
• •No diffuse bronchoalveolar carcinoma
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •Karnofsky 70-100%
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Not specified
• •Hepatic:
• •Not specified
• •Renal:
• •Not specified
• •Other:
• •No other malignancy within the past 5 years except nonmelanomatous skin cancer or noninvasive cervical carcinoma
• •No other medical illness that cannot be adequately controlled with appropriate therapy or that is considered severe enough to preclude a radical treatment approach
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No prior biologic therapy for lung cancer
• •Chemotherapy
• •No prior chemotherapy for lung cancer
• •Endocrine therapy
• •No prior endocrine therapy for lung cancer
• •Radiotherapy
• •No prior radiotherapy for lung cancer
• •Surgery
• •No prior surgery for lung cancer